Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M34,315Revenue $M2,234Net Margin (%)26.0Altman Z-Score25.0
Enterprise Value $M32,551EPS $3.3Operating Margin %33.7Piotroski F-Score6
P/E(ttm)58.9Beneish M-Score-2.5Pre-tax Margin (%)33.8Higher ROA y-yY
Price/Book9.810-y EBITDA Growth Rate %--Quick Ratio4.6Cash flow > EarningsY
Price/Sales15.35-y EBITDA Growth Rate %52.3Current Ratio4.9Lower Leverage y-yN
Price/Free Cash Flow66.9y-y EBITDA Growth Rate %23.9ROA % (ttm)15.2Higher Current Ratio y-yN
Dividend Yield %--PEG1.1ROE % (ttm)19.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M200ROIC % (ttm)39.2Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 171.94-5%Reduce 72.94%23,261
ALXNRon Baron 2015-03-31 Add0.02%$171.42 - $189.07
($181.01)
$ 171.94-5%Add 124.13%41,163
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 171.94-7%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 171.94-7%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 171.945%Reduce 89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 171.945%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 171.949%Add 240.11%17,094
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 171.949%New holding5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 171.949%New holding10,218
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 171.9485%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 171.9475%New holding12,977
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 171.9489%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 171.94127%New holding50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 171.94206%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 171.94259%New holding13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 171.94259%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$40.665 - $49.865
($45.18)
$ 171.94281%Add 90.48%8,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.7)
$ 171.94369%Reduce 87.61%8,400
ALXNGeorge Soros 2010-09-30 Buy 0.03%$24.82 - $32.49
($28.22)
$ 171.94509%New holding67,800
ALXNGeorge Soros 2010-06-30 Sold Out -0.17%$24.31 - $28.34
($26.53)
$ 171.94548%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Monnet DominiqueSVP, Chief Marketing Officer 2015-05-20Sell256$162.45.87view
MACKAY MARTINEVP & Global Head of R&D 2015-05-14Sell4,056$160.337.24view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-04-27Sell6,032$181.57-5.3view
BELL LEONARDCEO 2015-03-19Sell15,952$188.07-8.58view
O'Neill JulieEVP. Global Operations 2015-03-02Sell11,665$101.4969.42view
Sinha VikasEVP & CFO 2015-03-02Sell487$180.34-4.66view
MACKAY MARTINEVP & Global Head of R&D 2015-03-02Sell370$180.34-4.66view
Moriarty John BEVP & General Counsel 2015-03-02Sell280$180.34-4.66view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-03-02Sell228$180.34-4.66view
Carmichael ClareEVP, Chief HR Officer 2015-03-02Sell706$180.34-4.66view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
    Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
    Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
    Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
    CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 26 2013 

    More From Other Websites
    Summer stock picks May 22 2015
    A Beautiful Biotech Summer? May 22 2015
    Pall-Danaher Transaction: What You Should Know about Danaher May 21 2015
    Pall-Danaher Transaction: An Overview of Pall May 21 2015
    Achillion Dives As J&J Hep C Deal Chills Buyout Buzz May 20 2015
    Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J May 20 2015
    Do R&D Costs Matter When It Comes To Drug Pricing? May 20 2015
    Should You Set Up the Synageva BioPharma–Alexion Spread? May 14 2015
    Platinum picks for your portfolio May 14 2015
    Alexion Pharmaceuticals: A Focus on Treating Rare Disorders May 13 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 12 2015
    The Synageva–Alexion Merger: Stock and Cash Considerations May 12 2015
    Alexion Pharmaceuticals Pays up to Get Synageva BioPharma May 12 2015
    Disruptor 50: No.1 Moderna Therapeutics May 12 2015
    A hot biotech that may be the next Genentech May 12 2015
    Alexion to Present at Investor Conferences May 11 2015
    SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout May 08 2015
    Jobs report saves Dow, S&P 500 from losses May 08 2015
    2 reasons we're not in biotech bubble: Pro May 08 2015
    Jobless Claims Are Driven by Technology: XLK Up and QQQ Gains May 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK